Unlisted Shares
Veeda Clinical Research Limited
Verified Unlisted CompanyOff-market Transfer · NSDL / CDSL
About Veeda Clinical Research Limited
Veeda Clinical Research Limited is a contract research organization (CRO) providing clinical research and bioequivalence studies to pharmaceutical and biotechnology companies. Founded in 2004, the company offers a wide range of services including early-phase clinical trials, BA/BE studies, and analytical testing.
Share Details
| company Name | Veeda Clinical Research Limited |
| indicative Unlisted Share Price | ₹575 |
| market Capitalization | ₹2947 Crore |
| lot Size | 100 |
| 52 Week High | ₹480 |
| 52 Week Low | ₹448 |
| face Value | ₹2 |
| book Value | 131.38 |
| pe Ratio | N/A |
| pb Ratio | 3.41 |
| debt To Equity | 0.47 |
| return On Equity | -7.77 |
| total Outstanding Shares | 65777495 |
| isin | INE0HO401026 |
| depository | NSDL & CDSL |
| pan | AAECC3853U |
| cin | U73100GJ2004PLC044023 |
| rta | Link Intime India Pvt Ltd |
Income Statement (Profit & Loss) (₹ in Crore)
| Particulars | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | 268 | 409 | 368 | 610 |
| EBITDA | 62 | 103 | 53 | 125 |
| PBT | 65 | 62 | 3.2 | -66 |
| Net Profit / Loss (PAT) | 50 | 42 | -0.3 | -67 |
| EPS | 9.46 | 8 | -0.04 | -10.19 |
Key Financial Ratios (Last 3–5 Years)
| Ratio | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Operating Profit Margin (%) | 21.53 | 25.18 | 13.86 | 20.49 |
| Net Profit Margin (%) | 17.86 | 10.27 | -0.08 | -10.98 |
| Earning Per Share (Diluted) | 9.46 | 8 | -0.04 | -10.19 |
Financial Annual Report Summary
The company showed strong profitability in earlier years but has seen a decline in margins and turned loss-making in FY25. Revenue growth remains steady, but rising costs and operational challenges have impacted profitability.
Why Invest in Veeda Clinical Research
- Revenue growing strongly.
- Margins volatile and declining.
- Turned loss-making in FY25.
- Moderate leverage (D/E ~0.47).
- CRO sector has long-term potential but execution matters.
Balance Sheet - Assets (₹ in Crore)
| Item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Fixed Assets | 185 | 236 | 190 | 582 |
| CWIP | 120 | 22 | 33 | 25 |
| Investments | 88 | 55 | 80 | 41 |
| Trade Receivables | 98 | 105 | 120 | 77 |
| Inventory | 8 | 7 | 7.2 | 8 |
| Other Assets | 278 | 310 | 1,610 | 1,130 |
| Total Assets | 677 | 735 | 2,040.2 | 1,863 |
Balance Sheet - Liabilities & Equity (₹ in Crore)
| Item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Share Capital | 10.57 | 10.5 | 13.59 | 13.55 |
| FV | 2 | 2 | 2 | 2 |
| Reserves | 426 | 452 | 1,047 | 849 |
| Borrowings | 47 | 48 | 280 | 406 |
| Trade Payables | 25 | 22 | 27 | 47.5 |
| Other Liabilities | 168.43 | 202.5 | 473 | 547.34 |
| Total Liabilities | 677 | 735 | 2,040.6 | 1,863 |
Liabilities Breakdown & Balance Sheet Insights
Balance Sheet Insights
Rapid expansion with increasing debt and asset base.
Liabilities Breakdown
Debt to Equity ratio of 0.47 indicates moderate leverage.
Additional Insights
Expansion-led growth with rising borrowings.
Cash Flow Insights
- Heavy capex investment.
- Negative operating cash flow in latest year.
- Dependent on financing for expansion.
Shareholding Pattern
Recent
Promoter: High
Institutional: Moderate
Public: Low
Promoters & Management
Experienced promoters in clinical research industry.
Key Management
Not Available
Registrar & Transfer Agent (RTA)
Registrar: Link Intime India Pvt Ltd
Website: https://linkintime.co.in/
Management Analysis
Focused on scaling CRO capabilities and global client base.
Frequently Asked Questions About Veeda Clinical Research Limited
Explore More Investment Opportunities
Discover IPOs, unlisted shares, and broker comparison tools curated for smart investors.